Valeritas (NASDAQ:VLRX) Price Target Raised to $12.00

Valeritas (NASDAQ:VLRX) had its price objective boosted by Oppenheimer from $1.25 to $12.00 in a report issued on Tuesday morning, The Fly reports. Oppenheimer currently has an outperform rating on the stock. Oppenheimer also issued estimates for Valeritas’ Q2 2019 earnings at ($2.90) EPS, Q3 2019 earnings at ($2.66) EPS, Q4 2019 earnings at ($2.53) EPS, FY2019 earnings at ($11.14) EPS and FY2020 earnings at ($9.37) EPS.

Separately, ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.

NASDAQ VLRX opened at $3.09 on Tuesday. The company’s 50-day moving average price is $3.00. Valeritas has a twelve month low of $2.10 and a twelve month high of $34.00. The company has a quick ratio of 2.81, a current ratio of 3.32 and a debt-to-equity ratio of 29.19. The stock has a market capitalization of $19.91 million, a P/E ratio of -0.09 and a beta of 1.77.



Valeritas (NASDAQ:VLRX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.15). Valeritas had a negative return on equity of 1,757.04% and a negative net margin of 183.53%. The business had revenue of $6.40 million for the quarter, compared to the consensus estimate of $6.20 million. Analysts expect that Valeritas will post -11.14 earnings per share for the current year.

In other news, major shareholder Armistice Capital Master Fund purchased 226,000 shares of the stock in a transaction on Tuesday, May 21st. The shares were acquired at an average price of $0.66 per share, for a total transaction of $149,160.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have acquired 350,000 shares of company stock worth $234,640 in the last 90 days. Company insiders own 1.02% of the company’s stock.

Several large investors have recently made changes to their positions in VLRX. Weiss Multi Strategy Advisers LLC bought a new position in shares of Valeritas during the fourth quarter valued at about $41,000. Northern Trust Corp grew its stake in shares of Valeritas by 855.4% in the fourth quarter. Northern Trust Corp now owns 185,469 shares of the company’s stock worth $60,000 after purchasing an additional 166,057 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Valeritas by 138.0% in the fourth quarter. Geode Capital Management LLC now owns 186,971 shares of the company’s stock worth $60,000 after purchasing an additional 108,416 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Valeritas in the fourth quarter worth about $165,000. Finally, CVI Holdings LLC bought a new stake in shares of Valeritas in the fourth quarter worth about $832,000.

Valeritas Company Profile

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.

Further Reading: What is a CD ladder?

The Fly

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.